2026 ICD-10-CM Diagnosis Code D47.3Essential (hemorrhagic) thrombocythemia
ICD-10-CM Codes›C00–D49›D37-D48›D47
- Billable — Valid for Submission
- Risk Adjusts — HCC 23
- Not Chronic
D47.3 is a billable ICD-10-CM diagnosis code for essential (hemorrhagic) thrombocythemia. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 814 through 816. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Coagulation and hemorrhagic disorders and Neoplasms of unspecified nature or uncertain behavior.
For Medicare Advantage risk adjustment, D47.3 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2026.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
D47.3 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.
Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Congenital splenomegaly
- Essential thrombocythemia
- Familial thrombocytosis
- Increased platelet production
- Myelofibrosis
- Myelofibrosis due to another disorder
- Platelet count above reference range
- Platelet production finding
- Post-essential thrombocythemia myelofibrosis
- Thrombocythemia with distal limb defect
- Thrombocytosis
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Essential thrombocytosis
- Idiopathic hemorrhagic thrombocythemia
- Primary thrombocytosis
Type 2 Excludes
- reactive thrombocytosis D75.838
- secondary thrombocytosis D75.838
- thrombocythemia NOS D75.839
- thrombocytosis NOS D75.839
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
A type 2 excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Thrombocythemia (hemorrhagic) See Also: Thrombocytosis; D75.839
essential D47.3
idiopathic D47.3
primary D47.3
essential D47.3
idiopathic D47.3
primary D47.3
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Thrombocythemia, Essential
a clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.Thrombocytosis
increased numbers of platelets in the peripheral blood. (dorland, 27th ed)
Patient EducationClinical
Platelet Disorders
Platelets, also known as thrombocytes, are blood cells. They form in your bone marrow, a sponge-like tissue in your bones. Platelets play a major role in blood clotting. Normally, when one of your blood vessels is injured, you start to bleed.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert D47.3 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About D47.3Overview
What is the ICD-10 code for essential (hemorrhagic) thrombocythemia?
The ICD-10-CM code for essential (hemorrhagic) thrombocythemia is D47.3 (sometimes written as D473). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Is D47.3 a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report essential (hemorrhagic) thrombocythemia on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does D47.3 group to?
When essential (hemorrhagic) thrombocythemia is the principal diagnosis on an inpatient stay, it groups to MS-DRG 814, 815, 816, with relative weights from 0.6320 to 2.1267 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of D47.3?
Under the General Equivalence Mappings, essential (hemorrhagic) thrombocythemia converts to ICD-9-CM 238.71 (essntial thrombocythemia). The mapping is approximate, so confirm the match fits the documentation.
What HCC is D47.3?
D47.3 (essential (hemorrhagic) thrombocythemia) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 48 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 21.
Does D47.3 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, D47.3 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.
